EP2822646A4 - Modulating afferent signals to treat medical conditions - Google Patents

Modulating afferent signals to treat medical conditions

Info

Publication number: EP2822646A4
Authority: EP; European Patent Office
Prior art keywords: medical conditions; treat medical; afferent signals; modulating; modulating afferent
Prior art date: 2012-03-09
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Granted

Application number

EP13757567.6A

Other languages

German (de)

French (fr)

Other versions

EP2822646A1 (en

EP2822646B1 (en

Inventor

Michael J Joyner

Bruce D Johnson

Thomas P Olson

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Mayo Foundation for Medical Education and Research

Original Assignee

Mayo Foundation for Medical Education and Research

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2012-03-09

Filing date

2013-03-08

Publication date

2016-04-27

2013-03-08 Application filed by Mayo Foundation for Medical Education and Research filed Critical Mayo Foundation for Medical Education and Research

2015-01-14 Publication of EP2822646A1 publication Critical patent/EP2822646A1/en

2016-04-27 Publication of EP2822646A4 publication Critical patent/EP2822646A4/en

2023-10-18 Application granted granted Critical

2023-10-18 Publication of EP2822646B1 publication Critical patent/EP2822646B1/en

Status Active legal-status Critical Current

2033-03-08 Anticipated expiration legal-status Critical

Links

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N1/00—Electrotherapy; Circuits therefor
- A61N1/18—Applying electric currents by contact electrodes
- A61N1/32—Applying electric currents by contact electrodes alternating or intermittent currents
- A61N1/36—Applying electric currents by contact electrodes alternating or intermittent currents for stimulation
- A61N1/3605—Implantable neurostimulators for stimulating central or peripheral nerve system
- A61N1/3606—Implantable neurostimulators for stimulating central or peripheral nerve system adapted for a particular treatment
- A61N1/36114—Cardiac control, e.g. by vagal stimulation
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/235—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group
- A61K31/24—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group having an amino or nitro group
- A61K31/245—Amino benzoic acid types, e.g. procaine, novocaine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4468—Non condensed piperidines, e.g. piperocaine having a nitrogen directly attached in position 4, e.g. clebopride, fentanyl
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N1/00—Electrotherapy; Circuits therefor
- A61N1/18—Applying electric currents by contact electrodes
- A61N1/32—Applying electric currents by contact electrodes alternating or intermittent currents
- A61N1/36—Applying electric currents by contact electrodes alternating or intermittent currents for stimulation
- A61N1/3605—Implantable neurostimulators for stimulating central or peripheral nerve system
- A61N1/36057—Implantable neurostimulators for stimulating central or peripheral nerve system adapted for stimulating afferent nerves
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N1/00—Electrotherapy; Circuits therefor
- A61N1/18—Applying electric currents by contact electrodes
- A61N1/32—Applying electric currents by contact electrodes alternating or intermittent currents
- A61N1/36—Applying electric currents by contact electrodes alternating or intermittent currents for stimulation
- A61N1/3605—Implantable neurostimulators for stimulating central or peripheral nerve system
- A61N1/3606—Implantable neurostimulators for stimulating central or peripheral nerve system adapted for a particular treatment
- A61N1/3611—Respiration control
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N1/00—Electrotherapy; Circuits therefor
- A61N1/18—Applying electric currents by contact electrodes
- A61N1/32—Applying electric currents by contact electrodes alternating or intermittent currents
- A61N1/36—Applying electric currents by contact electrodes alternating or intermittent currents for stimulation
- A61N1/3605—Implantable neurostimulators for stimulating central or peripheral nerve system
- A61N1/3606—Implantable neurostimulators for stimulating central or peripheral nerve system adapted for a particular treatment
- A61N1/36114—Cardiac control, e.g. by vagal stimulation
- A61N1/36117—Cardiac control, e.g. by vagal stimulation for treating hypertension
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N1/00—Electrotherapy; Circuits therefor
- A61N1/18—Applying electric currents by contact electrodes
- A61N1/32—Applying electric currents by contact electrodes alternating or intermittent currents
- A61N1/36—Applying electric currents by contact electrodes alternating or intermittent currents for stimulation
- A61N1/3605—Implantable neurostimulators for stimulating central or peripheral nerve system
- A61N1/36128—Control systems
- A61N1/36146—Control systems specified by the stimulation parameters
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N2/00—Magnetotherapy
- A61N2/02—Magnetotherapy using magnetic fields produced by coils, including single turn loops or electromagnets
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P23/00—Anaesthetics

Landscapes

Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Radiology & Medical Imaging (AREA)
Biomedical Technology (AREA)
Engineering & Computer Science (AREA)
Neurology (AREA)
Neurosurgery (AREA)
Pharmacology & Pharmacy (AREA)
Medicinal Chemistry (AREA)
Chemical & Material Sciences (AREA)
Epidemiology (AREA)
Heart & Thoracic Surgery (AREA)
Cardiology (AREA)
Emergency Medicine (AREA)
Pulmonology (AREA)
Anesthesiology (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Electrotherapy Devices (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

EP13757567.6A 2012-03-09 2013-03-08 Modulating afferent signals to treat medical conditions Active EP2822646B1 (en)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US201261609169P	2012-03-09	2012-03-09
PCT/US2013/029930 WO2013134667A1 (en)	2012-03-09	2013-03-08	Modulating afferent signals to treat medical conditions

Publications (3)

Publication Number	Publication Date
EP2822646A1 EP2822646A1 (en)	2015-01-14
EP2822646A4 true EP2822646A4 (en)	2016-04-27
EP2822646B1 EP2822646B1 (en)	2023-10-18

Family

ID=49117391

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
EP13757567.6A Active EP2822646B1 (en)	2012-03-09	2013-03-08	Modulating afferent signals to treat medical conditions

Country Status (3)

Country	Link
US (3)	US10300281B2 (en)
EP (1)	EP2822646B1 (en)
WO (1)	WO2013134667A1 (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO2013134667A1 (en)	2012-03-09	2013-09-12	Mayo Foundation For Medical Education And Research	Modulating afferent signals to treat medical conditions
WO2017146659A1 (en) *	2016-02-24	2017-08-31	Cakmak Yusuf Ozgur	A system for decreasing the blood pressure
KR102068290B1 (en) *	2017-02-10	2020-01-20	서울대학교산학협력단	Pharmaceutical composition for the prevention or treatment of afferent nerve diseases comprising Tentonin 3 and use thereof

Citations (2)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US20030216792A1 (en) *	2002-04-08	2003-11-20	Levin Howard R.	Renal nerve stimulation method and apparatus for treatment of patients
WO2006022790A1 (en) *	2002-04-08	2006-03-02	Ardian, Inc.	Methods and devices for renal nerve blocking

Family Cites Families (43)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US3991770A (en)	1974-01-24	1976-11-16	Leveen Harry H	Method for treating benign and malignant tumors utilizing radio frequency, electromagnetic radiation
US5811463A (en)	1993-10-06	1998-09-22	University Of British Columbia	Compositions and method for relaxing smooth muscles
US5527307A (en)	1994-04-01	1996-06-18	Minimed Inc.	Implantable medication infusion pump with discharge side port
US6558351B1 (en)	1999-06-03	2003-05-06	Medtronic Minimed, Inc.	Closed loop system for controlling insulin infusion
ATE499988T1 (en)	2000-03-02	2011-03-15	Microchips Inc	MICROMECHANICAL DEVICES AND METHODS FOR STORAGE AND SELECTIVE EXPOSURE OF CHEMICALS
DE60116520T2 (en)	2000-10-10	2006-08-31	Microchips, Inc., Bedford	MICROCHIP RESERVOIR DEVICES WITH WIRELESS TRANSMISSION OF ENERGY AND DATA
US6928320B2 (en)	2001-05-17	2005-08-09	Medtronic, Inc.	Apparatus for blocking activation of tissue or conduction of action potentials while other tissue is being therapeutically activated
US20060116736A1 (en) *	2001-07-23	2006-06-01	Dilorenzo Daniel J	Method, apparatus, and surgical technique for autonomic neuromodulation for the treatment of obesity
US7204823B2 (en)	2001-12-19	2007-04-17	Medtronic Minimed, Inc.	Medication delivery system and monitor
US20110207758A1 (en)	2003-04-08	2011-08-25	Medtronic Vascular, Inc.	Methods for Therapeutic Renal Denervation
US8145316B2 (en) *	2002-04-08	2012-03-27	Ardian, Inc.	Methods and apparatus for renal neuromodulation
US20080213331A1 (en)	2002-04-08	2008-09-04	Ardian, Inc.	Methods and devices for renal nerve blocking
US20050065553A1 (en) *	2003-06-13	2005-03-24	Omry Ben Ezra	Applications of vagal stimulation
US7292890B2 (en)	2002-06-20	2007-11-06	Advanced Bionics Corporation	Vagus nerve stimulation via unidirectional propagation of action potentials
US20040172084A1 (en)	2003-02-03	2004-09-02	Knudson Mark B.	Method and apparatus for treatment of gastro-esophageal reflux disease (GERD)
US7613515B2 (en)	2003-02-03	2009-11-03	Enteromedics Inc.	High frequency vagal blockage therapy
US20050075702A1 (en) *	2003-10-01	2005-04-07	Medtronic, Inc.	Device and method for inhibiting release of pro-inflammatory mediator
US7232435B2 (en)	2004-02-06	2007-06-19	Medtronic, Inc.	Delivery of a sympatholytic cardiovascular agent to the central nervous system to counter heart failure and pathologies associated with heart failure
CN101010724B (en)	2004-08-27	2011-05-25	松下电器产业株式会社	Audio encoder
EP1904160B1 (en)	2005-06-09	2011-12-21	Medtronic, Inc.	Peripheral nerve field stimulation and spinal cord stimulation
US20070073354A1 (en)	2005-09-26	2007-03-29	Knudson Mark B	Neural blocking therapy
US20070196510A1 (en)	2006-02-17	2007-08-23	Gerber Michael J	Method for treating resistant hypertension
AU2007217100A1 (en)	2006-02-17	2007-08-30	Gilead Colorado, Inc.	Antihypertensive therapy
US20070275035A1 (en)	2006-05-24	2007-11-29	Microchips, Inc.	Minimally Invasive Medical Implant Devices for Controlled Drug Delivery
US8768469B2 (en) *	2008-08-08	2014-07-01	Enteromedics Inc.	Systems for regulation of blood pressure and heart rate
US20100114244A1 (en)	2008-10-31	2010-05-06	Medtronic, Inc.	Electrical renal autonomic blockade
US9370654B2 (en)	2009-01-27	2016-06-21	Medtronic, Inc.	High frequency stimulation to block laryngeal stimulation during vagal nerve stimulation
US8399443B2 (en)	2009-04-22	2013-03-19	Mercator Medsystems, Inc.	Treatment of hypertension by renal vascular delivery of guanethidine
US20140074076A1 (en)	2009-10-12	2014-03-13	Kona Medical, Inc.	Non-invasive autonomic nervous system modulation
US8825164B2 (en)	2010-06-11	2014-09-02	Enteromedics Inc.	Neural modulation devices and methods
US9782592B2 (en)	2010-07-15	2017-10-10	Boston Scientific Neuromodulation Corporation	Energy efficient high frequency nerve blocking technique
EP4137199A1 (en)	2010-11-17	2023-02-22	Medtronic Ireland Manufacturing Unlimited Company	Systems for therapeutic renal neuromodulation for treating dyspnea
US20130261368A1 (en)	2011-09-23	2013-10-03	Alan N. Schwartz	Non-invasive and minimally invasive and tightly targeted minimally invasive therapy methods and devices for parathyroid treatment
CN104254367A (en)	2012-03-07	2014-12-31	美敦力阿迪安卢森堡有限公司	Selective modulation of renal nerves
WO2013134121A2 (en)	2012-03-07	2013-09-12	Enteromedics Inc.	Devices for regulation of blood pressure and heart rate
WO2013134667A1 (en)	2012-03-09	2013-09-12	Mayo Foundation For Medical Education And Research	Modulating afferent signals to treat medical conditions
US20150080926A1 (en)	2012-04-27	2015-03-19	Medtronic Ardian Luxembourg S.A.R.L.	Ultrasound apparatuses, systems, and methods for renal neuromodulation
WO2014078301A1 (en)	2012-11-13	2014-05-22	Silk Road Medical, Inc.	Devices and methods for endoluminal delivery of either fluid or energy for denervation
US20170112564A1 (en)	2014-04-01	2017-04-27	Mayo Foundation For Medical Education And Research	Methods and materials for treating hypertension
WO2015153775A1 (en)	2014-04-01	2015-10-08	Mayo Foundation For Medical Education And Research	Methods and materials for treating elevated sympathetic nerve activity conditions
US9710881B2 (en)	2014-04-05	2017-07-18	Sony Interactive Entertainment America Llc	Varying effective resolution by screen location by altering rasterization parameters
WO2015164658A1 (en)	2014-04-24	2015-10-29	Sympara Medical, Inc.	Methods and devices for treating hypertension
US9393384B1 (en)	2015-08-17	2016-07-19	Tufts Medical Center, Inc.	Systems and methods for treating acute and chronic heart failure

2013
- 2013-03-08 WO PCT/US2013/029930 patent/WO2013134667A1/en active Application Filing
- 2013-03-08 EP EP13757567.6A patent/EP2822646B1/en active Active
- 2013-03-08 US US14/383,964 patent/US10300281B2/en active Active
2019
- 2019-05-21 US US16/418,307 patent/US11207519B2/en active Active
2021
- 2021-11-19 US US17/531,379 patent/US20220062637A1/en active Pending

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US20030216792A1 (en) *	2002-04-08	2003-11-20	Levin Howard R.	Renal nerve stimulation method and apparatus for treatment of patients
WO2006022790A1 (en) *	2002-04-08	2006-03-02	Ardian, Inc.	Methods and devices for renal nerve blocking

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
ANONYMOUS: "Classes of Heart Failure", 1 January 2015 (2015-01-01), XP002748697, Retrieved from the Internet <URL:http://www.heart.org/HEARTORG/Conditions/HeartFailure/AboutHeartFailure/Classes-of-Heart-Failure_UCM_306328_Article.jsp#.Vi5rdqNwbok> [retrieved on 20151026] *

Also Published As

Publication number	Publication date
EP2822646A1 (en)	2015-01-14
US20220062637A1 (en)	2022-03-03
US10300281B2 (en)	2019-05-28
US20150057313A1 (en)	2015-02-26
US20190269923A1 (en)	2019-09-05
US11207519B2 (en)	2021-12-28
EP2822646B1 (en)	2023-10-18
WO2013134667A1 (en)	2013-09-12

Legal Events

Date	Code	Title	Description
2014-12-12	PUAI	Public reference made under article 153(3) epc to a published international application that has entered the european phase	Free format text: ORIGINAL CODE: 0009012
2015-01-14	17P	Request for examination filed	Effective date: 20141001
2015-01-14	AK	Designated contracting states	Kind code of ref document: A1 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR
2015-01-14	AX	Request for extension of the european patent	Extension state: BA ME
2015-06-17	DAX	Request for extension of the european patent (deleted)
2016-04-27	RA4	Supplementary search report drawn up and despatched (corrected)	Effective date: 20160324
2017-09-15	STAA	Information on the status of an ep patent application or granted ep patent	Free format text: STATUS: EXAMINATION IS IN PROGRESS
2017-10-18	17Q	First examination report despatched	Effective date: 20170919
2020-04-30	REG	Reference to a national code	Ref country code: DE Ref legal event code: R079 Ref document number: 602013084810 Country of ref document: DE Free format text: PREVIOUS MAIN CLASS: A61N0001320000 Ipc: A61N0002020000 Ref country code: DE Ref legal event code: R079 Free format text: PREVIOUS MAIN CLASS: A61N0001320000 Ipc: A61N0002020000
2020-06-03	RIC1	Information provided on ipc code assigned before grant	Ipc: A61N 2/02 20060101AFI20200430BHEP Ipc: A61K 31/4468 20060101ALI20200430BHEP Ipc: A61K 31/245 20060101ALI20200430BHEP Ipc: A61P 23/00 20060101ALI20200430BHEP
2020-09-08	STAA	Information on the status of an ep patent application or granted ep patent	Free format text: STATUS: EXAMINATION IS IN PROGRESS
2021-08-10	STAA	Information on the status of an ep patent application or granted ep patent	Free format text: STATUS: EXAMINATION IS IN PROGRESS
2023-05-07	GRAP	Despatch of communication of intention to grant a patent	Free format text: ORIGINAL CODE: EPIDOSNIGR1
2023-05-07	STAA	Information on the status of an ep patent application or granted ep patent	Free format text: STATUS: GRANT OF PATENT IS INTENDED
2023-05-31	INTG	Intention to grant announced	Effective date: 20230508
2023-09-08	GRAS	Grant fee paid	Free format text: ORIGINAL CODE: EPIDOSNIGR3
2023-09-15	GRAA	(expected) grant	Free format text: ORIGINAL CODE: 0009210
2023-09-15	STAA	Information on the status of an ep patent application or granted ep patent	Free format text: STATUS: THE PATENT HAS BEEN GRANTED
2023-10-18	AK	Designated contracting states	Kind code of ref document: B1 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR
2023-10-18	REG	Reference to a national code	Ref country code: GB Ref legal event code: FG4D
2023-10-31	REG	Reference to a national code	Ref country code: CH Ref legal event code: EP
2023-11-08	REG	Reference to a national code	Ref country code: IE Ref legal event code: FG4D
2023-11-09	REG	Reference to a national code	Ref country code: DE Ref legal event code: R096 Ref document number: 602013084810 Country of ref document: DE
2023-12-13	P01	Opt-out of the competence of the unified patent court (upc) registered	Effective date: 20231106
2024-02-12	REG	Reference to a national code	Ref country code: LT Ref legal event code: MG9D
2024-02-21	REG	Reference to a national code	Ref country code: NL Ref legal event code: MP Effective date: 20231018
2024-03-15	REG	Reference to a national code	Ref country code: AT Ref legal event code: MK05 Ref document number: 1621894 Country of ref document: AT Kind code of ref document: T Effective date: 20231018
2024-03-29	PG25	Lapsed in a contracting state [announced via postgrant information from national office to epo]	Ref country code: NL Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20231018
2024-04-08	PG25	Lapsed in a contracting state [announced via postgrant information from national office to epo]	Ref country code: GR Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20240119
2024-04-09	PG25	Lapsed in a contracting state [announced via postgrant information from national office to epo]	Ref country code: IS Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20240218
2024-04-15	PG25	Lapsed in a contracting state [announced via postgrant information from national office to epo]	Ref country code: LT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20231018
2024-04-23	PG25	Lapsed in a contracting state [announced via postgrant information from national office to epo]	Ref country code: AT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20231018

Publication	Publication Date	Title
IL273912A (en)	2020-05-31	Treatment of thalamocortical dysrhythmia
IL243360A0 (en)	2016-02-29	Methods of modulating cftr activity
HK1211316A1 (en)	2016-05-20	Mirna modulators of thermogenesis mirna
EP2888256A4 (en)	2016-02-17	Heterocyclic modulators of hif activity for treatment of disease
EP2906696A4 (en)	2016-06-08	Methods for modulating c9orf72 expression
HK1205759A1 (en)	2015-12-24	Treatment of biomass
EP2822647A4 (en)	2015-11-04	Selective modulation of renal nerves
PT3461895T (en)	2020-09-08	Modulation of ube3a-ats expression
EP2888253A4 (en)	2016-01-06	Heterocyclic modulators of hif activity for treatment of disease
HK1206713A1 (en)	2016-01-15	Heterocyclic modulators of hif activity for treatment of disease hif
EP2831585A4 (en)	2015-12-02	Methods for increasing efficacy of cd37-based therapy
GB201309274D0 (en)	2013-07-10	Treatment Of Fuel
EP2822646A4 (en)	2016-04-27	Modulating afferent signals to treat medical conditions
EP2890459A4 (en)	2016-04-27	Non-invasive autonomic nervous system modulation
EP2844066A4 (en)	2015-11-25	Killing of bed bugs
EP2822574A4 (en)	2016-01-27	Methods for modulation of phosphorus and fgf23
EP2840081A4 (en)	2015-11-25	Use of a novel aminopyridine derivative to prevent or treat cancer
AP2014008006A0 (en)	2014-10-31	Treatment of acid mine drainage
IL236870B (en)	2019-11-28	Hydroxystatin derivatives for the treatment of arthrosis
GB201221118D0 (en)	2013-01-09	Methods of treatment
GB201216748D0 (en)	2012-10-31	Methods of treatment
GB201216740D0 (en)	2012-10-31	Methods of treatment
GB201206325D0 (en)	2012-05-23	Methods of treatment
GB201206330D0 (en)	2012-05-23	Methods of treatment
GB201206326D0 (en)	2012-05-23	Methods of treatment